Azacitidine In Compassionate Use: Response to Therapy, Survival, and Prognostic Factors In 200 Patients Diagnosed with MDS or AML
ASH Annual Meeting, Atlanta (2007)
AUTORES: Regina García, Dunia de Miguel LLorente, Joan Bargay, Teresa Bernal, Jose Ramón González Porras, Mar Tormo, Fernando Ramos, Andreu Lapiedra, Jose Falantes, Blanca Xicoy, Guillermo F Sanz, Benet Nomdedeu, Salut Brunet, Joaquín Sánchez, and Grupo Andaluz de Smd

Re-Evaluation of the Efficacy of Azacitidine (AZA) In Patients From the AZA-001 Study with Higher-Risk Myelodysplastic Syndromes (MDS) Classified by WHO Criteria and WPSS Risk
ASH Annual Meeting (2007)
AUTORES: Norbert Gattermann, Guillermo F. Sanz, Aristoteles Giagounidis, John F Seymour, Pierre Fenaux, Valeria Santini, Ghulam J. Mufti, Petra Muus, Fernando Ramos, Lela M. Lucy, CL Beach, and Lewis R. Silverman

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004)
ASH Annual Meeting (2007)
AUTORES: Pierre Fenaux, Aristotle Giagounidis, Dominik Selleslag, Odile Beyne-Rauzy, Ghulam J Mufti, Moshe Mittelman, Petra Muus, Peter te Boekhorst, Guillermo Sanz, Consuelo del Cañizo, Agnes Guerci-Bresler, Brigitte Schlegelberger, Carlo Aul, Hans Kreipe, Gudrun Goehring, Robert Knight, John Francis, Tommy Fu, and Eva Hellstrom-Lindberg

Myeloablative Conditioning with Intravenous Busulfan In One Daily Dose and Fludarabine (BUF) for HLA-Identical Sibling Allogeneic HSCT In Myeloid Malignancies
ASH Annual Meeting, Atlanta (2007)
AUTORES: Javier De la Serna, Jaime Sanz, Arancha Bermudez, Carlos Vallejo, David Serrano, Dolores Caballero, Rafael De La Camara, José M. Moraleda, Sonia Gonzalez, Ana García-Noblejas, M. Cabrero, Juan José Lahuerta, Arturo Iriondo, Luis Benlloch, and Guillermo Sanz